Compare Arm Holdings plc (ARM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arm Holdings plc vs Sana Biotechnology Inc — how do they compare? Arm Holdings plc trades at $306.61 (market cap $345.41B), while Sana Biotechnology Inc trades at $3.68 (market cap $1.07B). The key difference: Arm Holdings plc is far larger — about 322.8× Sana Biotechnology Inc's market cap, and Arm Holdings plc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| ARM | SANA | |
|---|---|---|
Market Cap | $345.41B | $1.07B |
Sector | Technology | Health |
52-Week High | $439.46 | $5.92 |
52-Week Low | $104.55 | $2.68 |
Enterprise Value | $342.26B | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
SANA Biotechnology trades at $3.85, down 2.04% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows significant losses with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve in 2026. Recent news highlights clinical data presentations and a $69M stock sale via ATM facility in May 2026.
Despite heavy losses, analyst sentiment is strongly bullish with 82% buy ratings, reflecting optimism for SANA's engineered cell therapies. Key risks include sustained cash burn and clinical trial outcomes. The stock's appeal hinges on pipeline success, making it suitable for risk-tolerant investors betting on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
